Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial

Background: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC). Patients and methods: In this multicenter phase II trial, patients with unresectable or metastatic PC who had progressed on single-agent Gem o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2007-04, Vol.18 (4), p.745-751
Hauptverfasser:	Boeck, S, Weigang-Köhler, K, Fuchs, M, Kettner, E, Quietzsch, D, Trojan, J, Stötzer, O, Zeuzem, S, Lordick, F, Köhne, C-H, Kröning, H, Steinmetz, T, Depenbrock, H, Heinemann, V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences CA-19-9 Antigen - blood Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Gastroenterology. Liver. Pancreas. Abdomen gemcitabine Glutamates - adverse effects Glutamates - therapeutic use Guanine - adverse effects Guanine - analogs & derivatives Guanine - therapeutic use Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged multitargeted antifolate Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - mortality Pemetrexed Pharmacology. Drug treatments second-line therapy Survival Rate Treatment Failure Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!